Biochemistry and Biomedicine

Infectious Disease

We focus on the properties of infectious diseases, the impact that they have on human and animal health and the development of new treatments.

Our researchers 

Dr John Armstrong

John Armstrong

We are studying how a much-studied single-celled organism, fission yeast, switches to a much more complex growth form of elaborate multicellular filaments. This provides an unprecedented opportunity to understand how eukaryotic cells differentiate at the molecular level, and may ultimatley lead to new ways to treat fungal infections, currently a major problem in medicine and agriculture.

For more information visit the Armstrong lab web site

Dr Stephen Hare

Stephen Hare

Work in my lab uses biochemistry, structural biology and microbiology to answer questions about how pathogenic bacteria survive in their host. Our focus at the moment are Neisseria species and we have a particular interest in how these bacteria are able to extract haem from human haemoglobin by employing receptors on their surface.

Dr Mark Paget

Mark PagetWe study the molecular biology of gene expression in bacteria with focus on the actinomycete family of bacteria. The large actinomycete family are Gram-postive bacteria with a high content of G+C in their DNA, and includes many bacteria of medical and indutrial importance. For example, the Streptomyces genus are famous as the source of most clinically useful antibiotics, whereas the major human pathogen Mycobacterium tuberculosis kills more people world-wide than any other single infectious agent. Our primary model organism is the genetically and physiologically well-characterised Streptomyces coelicolor. We have recently widened our interests to include the control of fermentation in the bioethanol-producing thermophile Geobacillus thermoglucosidasius.

For more information visit the Paget Lab website

Dr Chrisostomos Prodromou

Dr Prodromou

I am a senior lecturer working on molecular chaperones, especially Hsp90. I seek to understand the structural basis for the maturation and activation of Hsp90 client proteins and the interplay with its associated complexes. I use structural, biochemical and genetic techniques to achieve my aims. I have a number of collaborations with staff across the university in helping them understand the molecular basis of interactions within their systems.

I am also actively engaged in programs aimed at the discovery and development of novel small-molecule inhibitors with application as drugs for the treatment of cancer, infectious disease and Alzheimer's disease.

Professor Alison Sinclair

Alison SinclairCancer virus interactions with host cells Epstein Barr virus (EBV)

EBV is the causative agent of Burkitt's Lymphoma, Hodgkin's Disease, Nasopharyngeal Carcimoma and Lymphoproliferative diseases in immunocompromised people. By adulthood, most people are infected with EBV and the virus persists in the body for life.

Dr Sinclair's research research group investigate the interactions between EBV and host cells that direct whether the virus establishes latency and promotes cancer development or undergoes lytic replication - destroying the cell. Members of the group can be found under the "people" section.

For more information visit the Sinclair Lab website.

Professor Michelle West

Michelle West

The research in our laboratory is focussed on deciphering the mechanisms involved in B-cell transformation by the cancer-associated herpesvirus, Epstein-Barr virus (EBV).

For more information visit the West Lab website

Dr Edward Wright

Edward WrightAfter successfully completing a PhD in Molecular Virology at the University of Cambridge Dr Edward Wright undertook infectious disease research in Uganda at the Medical Research Council/Uganda Virus Research Institute AIDS Research Unit. Through subsequent posts at University College London, the University of Westminster and now as a Senior Lecturer at the University of Sussex he has an international reputation for research on the epidemiology and antigenicity of (re-)emerging viral zoonoses. Results from these studies are being applied to develop novel vaccines aimed at limiting the public health impact of these viruses.